Atezolizumab and bevacizumab in combination is in clinical development for treating adults with high risk
of hepatocellular carcinoma (HCC) coming back (recurring), after complete surgical removal
(resection/ablation) of the affected tissue. HCC is the most common type of primary liver cancer, which
affects men more than women, and is more likely to develop the older a person gets.
Atezolizumab with bevacizumab for patients with resected or ablated hepatocellular carcinoma who are at high risk for disease recurrence
Atezolizumab and bevacizumab in combination is in clinical development for treating adults with high risk of hepatocellular carcinoma (HCC) coming back (recurring), after complete surgical removal (resection/ablation) of the affected tissue.
Indications:
Hepatocellular carcinoma (HCC)
Therapeutic Areas:
Gastrointestinal Cancer
Year:
2022